Hello, everyone, and how are you this fine morning? Our day got off to a nice start, thanks to a warm and shiny sun enveloping the blissfully quiet Pharmalot campus. Our short people have departed for their respective destinations — the local schoolhouse and gainful employment — and we are busily tending to our own usual tasks — brewing cups of stimulation and hunting for items of interest. This, in fact, brings us to the menu of tidbits assembled below. So please indulge and dig in. Hope you have a smashing day and, as always, do keep in touch. …

Activists gathered for AIDSWatch, the nation’s largest annual constituent-based national HIV/AIDS advocacy conference, heckled CDC director Dr. Robert Redfield after he sidestepped questions about the exclusivity and cost of the HIV prevention drug Truvada, the  New York Daily News tells us. Gilead Sciences (GILD) licenses and makes the pill, but its exclusivity rights means people are paying as much as $1,600 each month for a drug that activists say should be available for $6. AIDS activists want the CDC to pursue royalties.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy